Acquired Company

Q32 Bio completed its merger with Homology Medicines on March 25, 2024, with the combined company trading under the ticker QTTB.

The fund invests at least 80% of its net assets (plus borrowings for investment purposes) in the underlying security and financial instruments with economic characteristics that, in combination, provide 200% leveraged exposure to the price of the underlying security, on a daily basis, consistent with the fund’s investment objective. It is non-diversified. Show more

Market Cap

0.00

52 Wk Range

$11.21 - $14.30

Previous Close

$12.17

Open

$12.93

Volume

3,214

Day Range

$12.56 - $12.93

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.00%

Institutional Own.

0.00%

Qtr Updated

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
HMI-102 Details Phenylketonuria	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HMI-203 Details Mucopolysaccharidosis type II, Rare genetic disease, Rare diseases, Genetic disorder, Hunter syndrome MPS II	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HMI-103 Details Phenylketonuria	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.